Phillips T L, Wasserman T H, Gomer C J, Lawrence G A, Levine M L, Sadee W, Penta J S, Rubin D J
Br J Cancer Suppl. 1978 Jun;3:276-80.
The initial results of a Phase I evaluation of misonidazole in the U.S.A. are described, as well as the U.S. National Cancer Institute programme for radiosensitizer development. A total of 12 patients have been given 1--6 doses of 1--2 g/m2. Serum levels ranged from 25--87 microgram/ml at 4--6 h. One patient has developed mild peripheral neuropathy. Urinary excretion was chiefly of a demethylated metabolite as measured by HPLC assay.
本文描述了美国米索硝唑一期评估的初步结果，以及美国国立癌症研究所的放射增敏剂研发计划。共有12名患者接受了1-6剂、每平方米1-2克的治疗。4-6小时时血清水平在25-87微克/毫升之间。一名患者出现了轻度周围神经病变。通过高效液相色谱法测定，尿液排泄主要是一种去甲基代谢物。
